Article Text

Download PDFPDF
N-acetyltransferase-2 polymorphism in Parkinson’s disease: the Rotterdam study
  1. B Sanjay Harhangia,
  2. Ben A Oostrab,
  3. Peter Heutinkb,
  4. Cornelia M van Duijna,
  5. Albert Hofmana,
  6. Monique M B Bretelera
  1. aDepartment of Epidemiology and Biostatistics, bDepartment of Clinical Genetics, Erasmus University Medical School, PO Box 1738, 3000 DR Rotterdam, The Netherlands
  1. Dr M M B Breteler, Department of Epidemiology and Biostatistics, Erasmus University Medical School, PO Box 1738, 3000 DR, Rotterdam, The Netherlands. Telephone 0031 104087489; fax 0031 104089382; email breteler{at}


The N-acetyltransferase-2 gene (NAT-2) has been associated with Parkinson’s disease. The genotype associated with slow acetylation has been reported to be increased in patients with Parkinson’s disease. Three mutant alleles M1, M2, and M3 of NAT-2 were investigated in 80 patients with idiopathic Parkinson’s disease and 161 age matched randomly selected controls from a prospective population based cohort study. The allelic frequencies and genotypic distributions in patients were very similar to those found in controls. In controls the frequency of the wild type allele increased significantly with age suggesting that the mutant alleles are associated with an increased risk of mortality. These findings suggest that NAT-2 polymorphism is not a major genetic determinant of idiopathic Parkinson’s disease, but may be a determinant of mortality in the general population.

  • Parkinson’s disease
  • N-acetyltransferase-2
  • genetics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.